Home » Topics » BioWorld Science

BioWorld Science
RSS

Anti-IL6R Mab BCD-089 begins phase III rheumatoid arthritis study

Jan. 22, 2020

Phase I study initiated for REN-001 in McArdle disease

Jan. 22, 2020

Phase I study of TAK-169 in relapsed or refractory multiple myeloma underway

Jan. 22, 2020

Signs of efficacy seen with ONCOS-102 and chemotherapy in mesothelioma trial

Jan. 22, 2020

Tepezza approved in the U.S. for thyroid eye disease

Jan. 22, 2020

TNFAIP1 is a tumor suppressor in heptocellular carcinoma

Jan. 22, 2020

Boehringer Ingelheim presents GPR142 agonists

Jan. 22, 2020

DFH Therapeutics and HHS describe betulinic acid derivatives for HIV infection

Jan. 22, 2020

AlzeCure Pharma discloses new Trk-A and Trk-B modulators

Jan. 22, 2020

Yale University divulges let-7 microRNA-activating compounds for endometriosis

Jan. 22, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...